DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20194637

Efficacy of risperidone and haloperidol in treatment of schizophrenia in tertiary care hospital

Lavanya Nagaraj, Naveen Kumar Madalageri

Abstract


Background: Schizophrenia is a chronic debilitating disease with significant morbidity and mortality that often requires either typical or atypical antipsychotic pharmacotherapy. Atypical antipsychotic drugs are preferred over typical because of lower risk of extra pyramidal side effects. As there is paucity of data in Indian population, the present study was taken up to evaluate the efficacy of haloperidol and risperidone in the treatment of schizophrenia.

Methods: It was a comparative study conducted on 60 patients of Schizophrenia for one year in a tertiary care hospital. The study subjects were randomly assigned into 2 groups of 30 patients each, where group 1 were treated with atypical antipsychotic drug risperidone and group 2 with typical antipsychotic drug Haloperidol and both groups received the treatment for one year. Efficacy was measured using positive and negative syndrome scale (PANSS), clinical global impression - severity of illness (CGI-S), clinical global impression - improvement (CGI-I) scales.

Results: Both haloperidol and risperidone were associated with comparable baseline to endpoint reduction in symptom severity. However, risperidone treated subjects had significantly greater decrease in symptom severity as measured by PANSS score and total score, CGI-S scale. However, there is no significant difference between two groups in terms of CGI-S score.

Conclusions: The reduction in positive, negative and general scores in risperidone treated patients were significant with that of haloperidol treated patients.


Keywords


Risperidone, Haloperidol, Efficacy, Typical antipsychotics, Atypical antipsychotics

Full Text:

PDF

References


Gelder MG, Lopez-Ibor. JJ, Andreasen N, editors. New Oxford Textbook of Psychiatry. Volume 1, 2ed. New York: Oxford University Press; 2000: 567-636.

Gosh A, Chakraborty K, Mattoo SK. Newer molecule in the treatment of schizophrenia: A clinical update. Indian J Pharmacol. 2011;43(2):105-12.

Sadock BJ, Sadock VA. Kaplan and Sadock’s Comprehensive textbook of psychiatry, 7th ed. USA: Lippincott Williams and Wilkins; 2000:89.

Lieberman AJ, Tollefson G, Tolen M, Dr. P.H, Green AI, Gur RE, et al, Comparative efficacy and safety of atypical antipsychotic drugs in first-episode psychosis: A randomized, double blind trial of olanzapine versus haloperidol. Am J Psychiatr. 2003;160:1396-404.

Bruton LL, Lazo JS, Parker KL, editors. Goodman and Gillman’s The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw hill; 2001: 485-507.

Kannabiran M, Singh V. Metabolic syndrome and atypical antipsychotic: A selective literature review. German J Psychiatr. 2008;11:111-22.

Kay SR, Fiszbein A, Opler LA The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76.

Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28-37.

Sarkhel S. Kaplan and Sadock's Synopsis of Psychiatry: Behavioral Sciences/ Clinical Psychiatry, 10th edition. Indian J Psychiatr. 2009;51(4):331.

Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 2002;159(2):255-62.

Lindenmayer JP, Khan A, Iskander A, Abad MT, Parker B. A Randomized Controlled Trial of Olanzapine versus Haloperidol in the Treatment of Primary Negative Symptoms and Neurocognitive Deficits in Schizophrenia. J Clin Psychiatr. 2007;68:368-79.

Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus Haloperidol in the Treatment of Schizophrenia and Schizoaffective and Schizophreniform Disorders: Results of an International Collaborative Trial. Am J Psychiatr. 1997;154:457-46.